Voyager Therapeutics (VYGR) Capital Expenditures Growth (1y) (2015 - 2026)
Voyager Therapeutics (VYGR) Capital Expenditures Growth (1y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,440.76 Bn | 66,440.47 Bn | - | 38.18% |
| 2 | Nanobiotix | 1,880.51 Bn | 1,880.45 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 467.94 Bn | 463.15 Bn | 1.35 Bn | -27.93% |
| 5 | Vertex Pharmaceuticals | 122.63 Bn | 115.38 Bn | 2.59 Bn | 227.76% |
| 6 | Regeneron Pharmaceuticals | 70.30 Bn | 61.54 Bn | 3.31 Bn | 0.57% |
| 7 | Belite Bio | 62.81 Bn | 62.81 Bn | - | - |
| 8 | Argenx Se | 55.78 Bn | 50.59 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.33 Bn | 34.32 Bn | 959.66 Mn | 143.40% |
| 10 | Voyager Therapeutics | 182.36 Mn | 40.88 Mn | - | -97.87% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -97.87% |
| Dec 31, 2025 | -1,095.48% |
| Sep 30, 2025 | -19.77% |
| Jun 30, 2025 | -64.27% |
| Mar 31, 2025 | 4,286.67% |
| Dec 31, 2024 | -79.47% |
| Sep 30, 2024 | -89.47% |
| Jun 30, 2024 | 776.81% |
| Mar 31, 2024 | -97.05% |
| Dec 31, 2023 | -19.08% |
| Sep 30, 2023 | 69.48% |
| Jun 30, 2023 | -297.39% |
| Mar 31, 2023 | 123.25% |
| Dec 31, 2022 | 526.17% |
| Sep 30, 2022 | 315.35% |
| Jun 30, 2022 | -150.66% |
| Mar 31, 2022 | -39.20% |
| Dec 31, 2021 | 319.12% |
| Sep 30, 2021 | -886.76% |
| Jun 30, 2021 | 424.29% |